Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing
Contemporary Clinical Trials · 2026
DOI: 10.1016/j.cct.2026.108217 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Jinghua An und 19 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; Indiana University School of Nursing, 600 Barnhill …. Hauptthemen laut MEDLINE: Genetic Testing, Genetic Counseling, Cancer Survivors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Lombardi Comprehensive Cancer Center, Georgetown University, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Despite national guidelines recommending germline genetic testing (GT) for cancer survivors at high risk for hereditary cancers, GT remains underutilized, particularly among underserved populations who experience significant population health differences and higher cancer mortality. Barriers at the individual, interpersonal, and system levels contribute to this underutilization. Proactive clinical outreach and technology-based tools such as chatbots may help address these barriers and streamline cancer genetic service delivery, but culturally tailored chatbot interventions have rarely been tested for efficacy in Black cancer survivors. This paper describes the formative research and protocol for a multisite, randomized controlled trial testing a streamlined care delivery model addressing multilevel barriers to GT uptake. METHODS: Using electronic health records from two health systems, we will proactively identify and enroll 428 Black patients who have a prior diagnosis of breast, ovarian, uterine, colorectal, prostate, or pancreatic cancer and meet national guideline criteria for genetic testing. Participants are randomized to either the Genetic Education Decision Assistant (GEDA), a chatbot-based intervention, or Enhanced Usual Care (EUC, a clinical letter recommending genetic counseling and testing). The primary outcome is genetic testing completion. Secondary outcomes include genetic counseling uptake, knowledge, psychological distress, and decision regret, satisfaction, and conflict. DISCUSSION: This ongoing trial addresses an important translational gap by developing and implementing an alternative care delivery model that includes a chatbot to provide streamlined cancer genetic services. If effective, this intervention has the potential to reduce population differences in cancer genetics care and guide cancer risk reduction, surveillance, and cascade testing. TRIAL REGISTRATION NUMBER: The trial is registered on clinicaltrials.gov (NCT06073626).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; Indiana University School of Nursing, 600 Barnhill Dr, Indianapolis, IN 46202, USA.
- Georgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA; Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research, 2115 Wisconsin Ave NW, W…
- Rutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
- Georgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA.
- Rutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; School of Public Health, Rutgers University, 683 Hoes Ln W, Piscataway, NJ 08854, USA.
- MedStar Health Research Institute, 10980 Grantchester Way 7th Floor, Columbia, MD 21044, USA.
Förderung
- NCI NIH HHS
- Lombardi Comprehensive Cancer Center, Georgetown University
- National Institutes of Health National Cancer Institute
- Georgetown University
- Indiana University
Zitieren
APA
An, J., Huq, M., Speiser, E., Grumet, S., Peshkin, B. N., Heidt, E., Adams-Campbell, L., Grisham, C., Tundealao, S., Yesha, R., Toppmeyer, D., Isaacs, C., Sorgen, L., Tan, N., Hooda-Nehra, A., Nix, M. A., Reed, D. J., Staton, J., Schwartz, M. D., & Kinney, A. Y. (2026). Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2026.108217
Vancouver
An J, Huq M, Speiser E, Grumet S, Peshkin BN, Heidt E, et al. Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2026.108217
BibTeX
@article{An2026,
author = {An, Jinghua and Huq, Maisha and Speiser, Erin and Grumet, Sherry and Peshkin, Beth N and Heidt, Emily and Adams-Campbell, Lucile and Grisham, Christopher and Tundealao, Samuel and Yesha, Rose and Toppmeyer, Deborah and Isaacs, Claudine and Sorgen, Lia and Tan, Naomi and Hooda-Nehra, Anupama and Nix, Melanie A and Reed, Dorothy J and Staton, Jimmie and Schwartz, Marc D and Kinney, Anita Y},
title = {Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing},
journal = {Contemporary Clinical Trials},
year = {2026},
doi = {10.1016/j.cct.2026.108217}
}
EUVIMED